JP Morgan Chase
VIRX

JP Morgan Chase’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

JP Morgan Chase’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-326
Closed -$175K – 4307
2014
Q4 		$175K Hold
326
– – ﹤0.01% 4048
2014
Q3 		$489K Buy
+326
New +$472K ﹤0.01% 3675

Other funds holding VIRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UCFA
United Capital Financial Advisors Irving, Texas $16.3B AUM 16.34% 1-Year Est. Return
WA
WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

JP Morgan Chase's VIRX Position: Q1 2025 in Review

JP Morgan Chase sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q1 2025, closing a stake of 721 shares — an estimated $116 sold.

JP Morgan Chase first reported a position in VIRX in Q4 2014 and held it in 30 quarters. The position peaked at $4.63M in Q3 2021. 7 funds tracked by Wall St. Rank hold VIRX as of Q1 2025.

  • JP Morgan Chase reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • JP Morgan Chase sold 721 Viracta Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $116.
  • JP Morgan Chase first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2014 and held it in 30 quarters.
  • JP Morgan Chase's Viracta Therapeutics, Inc. Common Stock position peaked at $4.63M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q1 2025.

Based on JP Morgan Chase's 13F filing for Q1 2025, filed 12 May 2025.